You are here: Industry Insights > Roivant

News List

Roivant Launches Respivant Sciences americanpharmaceuticalreview
September 18, 2018
Roivant Sciences announced the launch of Respivant Sciences, a biopharmaceutical company focused on the lives of patients suffering from serious respiratory diseases...
Nabriva, Roivant collaborate for China rights to novel antibiotic biospectrumasia
March 30, 2018
As part of the license agreement, Nabriva has granted a Roivant subsidiary an exclusive license to develop and commercialize lefamulin in the greater China region.
Roivant Licenses Diabetes Drug From Ligand Pharma biospace
March 08, 2018
Ligand Pharmaceuticals Inc. is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences GmbH for $20 million upfront.
SoftBank invests $1.1 billion in Roivant Sciences biospectrumasia
August 17, 2017
Roivant, which had one of the biggest initial public offerings in the history of the biotech industry, is a company that focuses on developing and commercializing novel therapies through subsidiary “Vants.”
Japanese telecom giant injects $1.1bn into Swiss biotech in largest-ever investment of its kind pharmafile
August 11, 2017
In possibly the biggest single biotech investment ever made, Swiss biotech firm Roivant has received a $1.1 billion cash injection thanks to an investment from Japanese telecom giant SoftBank.

Previous page 1 2 Next page